Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 71 to 80 of 511

TitleReference numberPublishedLast updated
Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)TA1006
Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and overTA1002
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia in people 12 years and overTA1003
Burosumab for treating X-linked hypophosphataemia in adultsTA993
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and overTA986
Baricitinib for treating juvenile idiopathic arthritis in people 2 years and over (terminated appraisal)TA982
Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people 12 years and over (terminated appraisal)TA980
Dabrafenib with trametinib for treating BRAF V600E mutation-positive glioma in children and young people aged 1 year and overTA977
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeHST31
Endoscopic duodenal mucosal resurfacing for insulin resistance in type 2 diabetesHTG721

Results per page

  1. 10
  2. 25
  3. 50
  4. All